Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins

  • Reis, Ana|||0000-0002-4537-9902
  • Rocha, Sara
  • Dias, Irundika HK.|||0000-0002-6620-8221
  • Costa, Raquel|||0000-0002-9245-4565
  • Soares, Raquel|||0000-0002-9157-5541
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
  • de Freitas, Victor|||0000-0003-0586-2278
The incidence of diabetes on the worldwide population has tripled in the past 5 decades. While drug-based therapies are valuable strategies to treat and ease the socio-economic burden of diabetes, nutritional strategies offer valuable alternatives to prevent and manage diabetes onset and contribute to the sustainability of health budgets. Whilst, intervention studies have shown that (poly)phenol-rich diets improve fasting glucose levels and other blood parameters, very little is known about the distribution of ingested polyphenols in circulation and the impact of diabetes on its cargo. In this study we investigate the impact of type 2 diabetes on the cargo of plasma (poly)phenols. Our results show that phenolic compounds are heterogeneously distributed in circulation though mainly transported by lipoprotein populations. We also found that diabetes has a marked effect on the phenolic content transported by VLDL resulting in the decrease in the content of flavonoids and consequently a decrease in the antioxidant capacity. In addition to the reduced bioavailability of (poly)phenol metabolites and increase of oxidative status in LDL and HDL populations in diabetes, cell-based assays show that sub-micromolar amounts of microbial (poly)phenol metabolites are able to counteract the pro-inflammatory status in glucose-challenged endothelial cells. Our findings highlight the relevance of triglyceride-rich lipoproteins in the transport and delivery of bioactive plant-based compounds to the endothelium in T2DM supporting the adoption of nutritional guidelines as an alternative strategy to drug-based therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Apolipoprotein J protects cardiomyocytes from lipid-mediated inflammation and cytotoxicity induced by the epicardial adipose tissue of diabetic patients

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Gil Millán, Pedro
  • Miñambres, Inka|||0000-0002-0899-3938
  • Ginel, Antonino|||0000-0002-8820-7545
  • Tauron, Manel|||0000-0002-5864-519X
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Diabetic patients present increased volume and functional alterations in epicardial adipose tissue (EAT). We aimed to analyze EAT from type 2 diabetic patients and the inflammatory and cytotoxic effects induced on cardiomyocytes. Furthermore, we analyzed the cardioprotective role of apolipoprotein J (apoJ). EAT explants were obtained from nondiabetic patients (ND), diabetic patients without coronary disease (DM), and DM patients with coronary disease (DM-C) after heart surgery. Morphological characteristics and gene expression were evaluated. Explants were cultured for 24 h and the content of nonesterified fatty acids (NEFA) and sphingolipid species in secretomes was evaluated by lipidomic analysis. Afterwards, secretomes were added to AC16 human cardiomyocytes for 24 h in the presence or absence of cardioprotective molecules (apoJ and HDL). Cytokine release and apoptosis/necrosis were assessed by ELISA and flow cytometry. The EAT from the diabetic samples showed altered expression of genes related to lipid accumulation, insulin resistance, and inflammation. The secretomes from the DM samples presented an increased ratio of pro/antiatherogenic ceramide (Cer) species, while those from DM-C contained the highest concentration of saturated NEFA. DM and DM-C secretomes promoted inflammation and cytotoxicity on AC16 cardiomyocytes. Exogenous Cer16:0, Cer24:1, and palmitic acid reproduced deleterious effects in AC16 cells. These effects were attenuated by exogenous apoJ. Diabetic secretomes promoted inflammation and cytotoxicity in cardiomyocytes. This effect was exacerbated in the secretomes of the DM-C samples. The increased content of specific NEFA and ceramide species seems to play a key role in inducing such deleterious effects, which are attenuated by apoJ.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of Epicardial Adipose Tissue with Novel Inflammation and Heart Failure Biomarkers in Type 2 Diabetes Patients, Effect of Metabolic Control

  • Gil, Pedro|||0000-0003-3707-7450
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Background : Type 2 diabetes (T2D patients) have a 74% increased risk of heart failure (HF), but traditional HF biomarkers lack sensitivity in early disease detection. Increased epicardial adipose tissue volume (EATv) is associated with cardiovascular risk in T2D, and novel biomarkers such as growth differentiation factor 15 (GDF15), Galectin-3, and soluble suppression of tumorigenicity 2 (sST2) are inflammation biomarkers linked to HF. Methods : We investigated associations between EATv, inflammation biomarkers, and the effect of metabolic control in 14 healthy controls (HCs) and 36 newly diagnosed T2D patients both before (poor glycemic control, PGC) and after 12 months of glycemic optimization (good glycemic control, GGC). EATv indexed to body surface area (iEATv) was quantified by multidetector computed tomography, and biomarker levels were measured by immunoassays. Results : PGC patients had higher iEATv (59.53 ± 21.67 vs. 36.84 ± 16.57 cm 3 /m 2, p = 0.0017) and elevated GDF15, Galectin-3, and sST2 levels (all p < 0.05) than HC subjects. The glycemic optimization reduced iEATv (p = 0.0232) and sST2 (p = 0.048), while GDF15 and Galectin-3 remained unchanged. Multivariable analysis confirmed independent associations between iEATv, GDF15 (β = 0.27, p = 0.027) and sST2 (β = 0.29, p = 0.02). Conclusions : These results support the link between systemic inflammation, EAT expansion, and cardiac dysfunction, and they point to the role of epicardial fat in early HF risk of T2D patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low-Density Lipoprotein Subfraction Phenotype Is Associated with Epicardial Adipose Tissue Volume in Type 2 Diabetes

  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Gil, Pedro|||0000-0003-3707-7450
  • Viladés Medel, David|||0000-0002-3638-9703
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Genua, Idoia|||0000-0001-6834-561X
  • Miñambres, Inka|||0000-0002-0899-3938
  • Grau-Agramunt, Margarida
  • Gich, Ignasi|||0000-0003-3975-6588
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Background : Increased epicardial adipose tissue (EAT) volume is a common feature in type 2 diabetes (T2DM) which is directly associated with heart failure and advanced atherosclerosis. We aimed to evaluate lipoprotein-related biomarkers of EAT volume in T2DM patients before and after glycemic control. Methods : This study included 36 T2DM patients before and after optimization of glycemic control and on 14 healthy controls (HCs). EAT volume was measured using computed tomography imaging indexed to the body surface area (iEAT). Biochemical and lipid profiles were determined using commercial methods. Lipoproteins were isolated by ultracentrifugation, and variables of lipoprotein function were assessed. Multivariable regression analysis was used to find variables independently associated with iEAT. Results : iEAT was higher in T2DM than in controls and decreased with glycemic optimization. HDLs from T2DM had less apoA-I and cholesterol and more apoC-III and triglycerides. LDLs from T2DM had more triglycerides and apoB and smaller sizes than those from HCs. Significant correlations were found between iEAT and age, BMI, HbA1c, GGT, VLDLc, triglycerides, LDL size, apoA-I in HDL, and apoC-III in HDL. In the multivariable regression analysis, age, LDL size, and GGT associations remained statistically significant, and predicted 50% of the variability in EAT volume. ROC analysis using these variables showed an AUC of 0.835. Conclusions : Qualitative characteristics of lipoproteins were altered in T2DM. Multivariable analysis showed that LDL size and GGT plasma levels were independently associated with iEAT volume, suggesting that these variables might be useful biomarkers for stratifying T2DM patients with increased EAT volume.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Altered small dense LDL profiles in long-standing controlled Type 1 Diabetes

  • Sardà, Helena|||0000-0002-0138-8217
  • Solé, Arnau|||0009-0007-6517-6188
  • Colom, Cristina|||0000-0002-2926-4697
  • Borràs, Carla|||0000-0002-0998-7855
  • Carreras, Gemma|||0000-0002-6718-8381
  • Benitez, Sonia|||0000-0003-3565-0743
  • Miñambres, Inka|||0000-0002-0899-3938
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Introduction: Small dense low-density lipoprotein (sdLDL) is a highly atherogenic LDL subclass associated with cardiovascular disease (CVD). While type 1 diabetes confers increased cardiovascular risk despite adequate glycemic control, the role of sdLDL and its regulators remains unclear. Methods: In this cross-sectional observational study, plasma from individuals with long-standing type 1 diabetes and 24 healthy controls was analyzed. sdLDL-cholesterol (sdLDL-C) concentration, sdLDL-C/LDL-cholesterol ratio, LDL size and subclasses were assessed using homogeneous assays, NMR spectroscopy, and gradient gel electrophoresis. Apolipoprotein C3 (ApoC3), hepatic lipase (HL), endothelial lipase (EL), and cholesteryl ester transfer protein (CETP) activity were measured by immunoturbidimetric, ELISA and functional assays. Results: Despite adequate glycemic control (mean HbA1c 7.6% [60 mmol/mol]) and near-normal lipid levels, individuals with type 1 diabetes had significantly higher sdLDL-C (0.56 ± 0.28 mmol/L vs 0.43 ± 0.26 mmol/L), increased sdLDL-C/LDL-cholesterol ratio (0.20 ± 0.08 vs 0.12 ± 0.06) and smaller LDL particle size (26.32 ± 1.08 nm vs 26.81 ± 0.68 nm) compared with controls. ApoC3 and HL mass/activity were significantly increased (8.67 ± 3.22 mg/dL vs 6.53 ± 2.42; 46.60 ± 16.12 ng/mL vs 15.45 ± 7.40 ng/mL and 1.03 ± 0.24 U/mL vs 0.89 ± 0.23 U/mL; respectively), CETP activity significantly reduced (808.8 ± 197.0 pmol/mL/h vs 929.7 ± 149.6 pmol/mL/h), and endothelial lipase levels unchanged. sdLDL-C positively correlated with ApoC3 (r = 0.7517) and inversely with CETP activity (r = -0.2682). Conclusion: Long-standing type 1 diabetes with adequate glycemic control is associated with an atherogenic sdLDL profile despite near-normal conventional lipid levels. This first multi-method characterization study of sdLDL in type 1 diabetes highlights the contribution of ApoC3, CETP and HL to sdLDL-C enrichment and suggests that direct assessment of sdLDL may improve cardiovascular risk stratification.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of distinctive sphingolipids in the inflammatory and apoptotic effects of electronegative LDL on monocytes

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Estruch, Montserrat|||0000-0002-7162-4158
  • Jin, Lei
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL(-)) is a minor LDL subfraction that is present in blood with inflammatory and apoptotic effects. We aimed to evaluate the role of sphingolipids ceramide (Cer), sphingosine (Sph), and sphingosine-1-phosphate (S1P) in the LDL(-)-induced effect on monocytes. Total LDL was subfractioned into native LDL and LDL(-) by anion-exchange chromatography and their sphingolipid content evaluated by mass spectrometry. LDL subfractions were incubated with monocytes in the presence or absence of enzyme inhibitors: chlorpromazine (CPZ), D-erythro-2-(N-myristoyl amino)-1-phenyl-1-propanol (MAPP), and N,N-dimethylsphingosine (DMS), which inhibit Cer, Sph, and S1P generation, respectively. After incubation, we evaluated cytokine release by enzyme-linked immunosorbent assay (ELISA) and apoptosis by flow cytometry. LDL(-) had an increased content in Cer and Sph compared to LDL(+). LDL(-)-induced cytokine release from cultured monocytes was inhibited by CPZ and MAPP, whereas DMS had no effect. LDL(-) promoted monocyte apoptosis, which was inhibited by CPZ, but increased with the addition of DMS. LDL enriched with Sph increased cytokine release in monocytes, and when enriched with Cer, reproduced both the apoptotic and inflammatory effects of LDL(-). These observations indicate that Cer content contributes to the inflammatory and apoptotic effects of LDL(-) on monocytes, whereas Sph plays a more important role in LDL(-)-induced inflammation, and S1P counteracts apoptosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Human ApoA-I overexpression enhances macrophage-specific reverse cholesterol transport but fails to prevent inherited diabesity in mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Farré, Núria|||0000-0003-3110-6572
  • Santos, David|||0000-0003-1157-4969
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Metso, Jari
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Errico, Teresa Laura
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Julve i Gil, Josep|||0000-0002-6531-2246
Human apolipoprotein A-I (hApoA-I) overexpression improves high-density lipoprotein (HDL) function and the metabolic complications of obesity. We used a mouse model of diabesity, the db/db mouse, to examine the effects of hApoA-I on the two main functional properties of HDL, i.e., macrophage-specific reverse cholesterol transport (m-RCT) in vivo and the antioxidant potential, as well as the phenotypic features of obesity. HApoA-I transgenic (hA-I) mice were bred with nonobese control (db/+) mice to generate hApoA-I-overexpressing db/+ offspring, which were subsequently bred to obtain hA-I-db/db mice. Overexpression of hApoA-I significantly increased weight gain and the incidence of fatty liver in db/db mice. Weight gain was mainly explained by the increased caloric intake of hA-I-db/db mice (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer's disease

  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, Maria del Mar
  • Tur, Silvia
  • Martinez Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer's disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Montolio, Lara
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Navarra, Laia
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL) (LDL(-)), a modified LDL that is present in blood and exerts atherogenic effects on endothelial cells and monocytes. This study aimed to determine the action of LDL(-) on monocytes differentiated into macrophages. LDL(-) and in vitro-modified LDLs (oxidized, aggregated, and acetylated) were added to macrophages derived from THP1 monocytes over-expressing CD14 (THP1-CD14). Then, cytokine release, cell differentiation, lipid accumulation, and gene expression were measured by ELISA, flow cytometry, thin-layer chromatography, and real-time PCR, respectively. LDL(-) induced more cytokine release in THP1-CD14 macrophages than other modified LDLs. LDL(-) also promoted morphological changes ascribed to differentiated macrophages. The addition of high-density lipoprotein (HDL) and anti-TLR4 counteracted these effects. LDL(-) was highly internalized by macrophages, and it was the major inductor of intracellular lipid accumulation in triglyceride-enriched lipid droplets. In contrast to inflammation, the addition of anti-TLR4 had no effect on lipid accumulation, thus suggesting an uptake pathway alternative to TLR4. In this regard, LDL(-) upregulated the expression of the scavenger receptors CD36 and LOX-1, as well as several genes involved in triglyceride (TG) accumulation. The importance and novelty of the current study is that LDL(-), a physiologically modified LDL, exerted atherogenic effects in macrophages by promoting differentiation, inflammation, and triglyceride-enriched lipid droplets formation in THP1-CD14 macrophages, probably through different receptors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide -[113-122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Rull, Anna|||0000-0002-8907-7754
  • Aldana-Ramos, Joile
  • Santos, David|||0000-0003-1157-4969
  • Puig, Nuria
  • Farre-Cabrerizo, Nuria
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pérez, Antonio|||0000-0001-5528-1143
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Mimetic peptides are potential therapeutic agents for atherosclerosis. -[113-122]apolipoprotein (apo) J (-[113-122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of -[113-122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with -[113-122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with -[113-122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of -[113-122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from -[113-122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with -[113-122]apoJ. Our results demonstrate that the -[113-122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue, A Multidetector Computed Tomography Study

  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Viladés Medel, David|||0000-0002-3638-9703
  • Martínez-Camblor, Pablo|||0000-0001-7845-3905
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Ferrero-Gregori, Andreu|||0000-0001-6492-2416
  • Nasarre, Laura
  • Bornachea, Olga
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Leta, Rubén|||0000-0003-4691-381X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Epicardial adipose tissue (EAT) constitutes a novel parameter for cardiometabolic risk assessment and a target for therapy. Here, we evaluated for the first time the plasma microRNA (miRNA) profile as a source of biomarkers for epicardial fat volume (EFV). miRNAs were profiled in plasma samples from 180 patients whose EFV was quantified using multidetector computed tomography. In the screening study, 54 deregulated miRNAs were identified in patients with high EFV levels (highest tertile) compared with matched patients with low EFV levels (lowest tertile). After filtering, 12 miRNAs were selected for subsequent validation. In the validation study, miR-15b-3p, miR-22-3p, miR-148a-3p miR-148b-3p and miR-590-5p were directly associated with EFV, even after adjustment for confounding factors (p value < 0.05 for all models). The addition of miRNA combinations to a model based on clinical variables improved the discrimination (area under the receiver-operating-characteristic curve (AUC) from 0.721 to 0.787). miRNAs correctly reclassified a significant proportion of patients with an integrated discrimination improvement (IDI) index of 0.101 and a net reclassification improvement (NRI) index of 0.650. Decision tree models used miRNA combinations to improve their classification accuracy. These results were reproduced using two proposed clinical cutoffs for epicardial fat burden. Internal validation corroborated the robustness of the models. In conclusion, plasma miRNAs constitute novel biomarkers of epicardial fat burden.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice

  • Méndez Lara, Karen Alejandra|||0000-0002-8372-2310
  • Santos, David|||0000-0003-1157-4969
  • Farré, Núria|||0000-0003-3110-6572
  • Ruiz-Nogales, Sheila
  • Leánez, Sergi
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Zapico Muñiz, Edgar|||0000-0002-8921-1167
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Pol, Olga|||0000-0002-4621-8457
The antinociceptive effects of the carbon monoxide-releasing molecule tricarbonyldichlororuthenium (II) dimer (CORM-2) during chronic pain are well documented, but most of its possible side-effects remain poorly understood. In this work, we examine the impact of CORM-2 treatment on the lipoprotein profile and two main atheroprotective functions attributed to high-density lipoprotein (HDL) in a mouse model of type 1 diabetes while analyzing the effect of this drug on diabetic neuropathy. Streptozotocin (Stz)-induced diabetic mice treated with CORM-2 (Stz-CORM-2) or vehicle (Stz-vehicle) were used to evaluate the effect of this drug on the modulation of painful diabetic neuropathy using nociceptive behavioral tests. Plasma and tissue samples were used for chemical and functional analyses, as appropriate. Two main antiatherogenic properties of HDL, i.e., the ability of HDL to protect low-density lipoprotein (LDL) from oxidation and to promote reverse cholesterol transport from macrophages to the liver and feces in vivo (m-RCT), were also assessed. Stz-induced diabetic mice displayed hyperglycemia, dyslipidemia and pain hypersensitivity. The administration of 10 mg/kg CORM-2 during five consecutive days inhibited allodynia and hyperalgesia and significantly ameliorated spinal cord markers (Cybb and Bdkrb1 expression) of neuropathic pain in Stz mice, but it did not reduce the combined dyslipidemia shown in Stz-treated mice. Its administration to Stz-treated mice led to a significant increase in the plasma levels of cholesterol (∼ 1.4-fold vs. Ctrl, ∼ 1.3- fold vs. Stz-vehicle; p < 0.05) and was attributed to significant elevations in both non-HDL (∼ 1.8-fold vs. Ctrl; ∼ 1.6-fold vs. Stz-vehicle; p < 0.05) and HDL cholesterol (∼ 1.3-fold vs. Ctrl, ∼ 1.2-fold vs. Stz-vehicle; p < 0.05). The increased HDL in plasma was not accompanied by a commensurate elevation in m-RCT in Stz-CORM-2 compared to Stz-vehicle mice; instead, it was worsened as revealed by decreased [ 3 H]-tracer trafficking into the feces in vivo. Furthermore, the HDL-mediated protection against LDL oxidation ex vivo shown by the HDL isolated from Stz-CORM-2 mice did not differ from that obtained in Stz-vehicle mice. In conclusion, the antinociceptive effects produced by a high dose of CORM-2 were accompanied by antioxidative effects but were without favorable effects on the dyslipidemia manifested in diabetic mice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes

  • Colom, Cristina|||0000-0002-2926-4697
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez-Cuellar, Montserrat
  • Leta, Rubén|||0000-0003-4691-381X
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Carreras, Gemma|||0000-0002-6718-8381
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The pathophysiology of cardiovascular complications in people with type 1 diabetes (T1DM) remains unclear. An increase in epicardial adipose tissue (EAT) and alterations in the composition of high-density lipoprotein (HDL) are associated with coronary artery disease, but information on its relationship in T1DM is very limited. Our aim was to determine the association between EAT volume, subclinical atherosclerosis, and HDL composition in type 1 diabetes. Seventy-two long-term patients with T1DM without clinical atherosclerosis were analyzed. EAT volume and subclinical atherosclerosis were measured using cardiac computed tomography angiography. EAT was adjusted according to body surface to obtain an EAT index (iEAT). HDL composition was determined. The mean iEAT was 40.47 ± 22.18 cc/m 2. The bivariate analysis showed positive associations of the iEAT with gender, age, hypertension, dyslipidemia, smoking, body mass index, waist circumference, insulin dose, and triglyceride (P < 0.05). The iEAT correlated positively with small HDL, increased content of apolipoprotein (apo)A-II and apoC-III, and decreased content of apoE and free cholesterol. Multiple linear regression showed that age, apoA-II content in HDL, and waist circumference were independently associated with the iEAT. Fifty percent of the patients presented subclinical atherosclerotic lesions. These patients had a higher iEAT, and their HDL contained less cholesterol and more apoA-II and lipoprotein-associated phospholipase A2 than patients without subclinical atherosclerosis. Alterations in the composition of HDL in TIDM are associated with increased iEAT and the presence of subclinical atherosclerosis. We propose that these abnormalities of HDL composition could be useful to identify T1DM patients at highest cardiovascular risk. The online version of this article (10.1186/s12933-018-0794-9) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity

  • Genua, Idoia|||0000-0001-6834-561X
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez, Sonia|||0000-0003-3565-0743
  • Gil, Pedro|||0000-0003-3707-7450
  • Grau-Agramunt, Margarida
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Balagué Ponz, Carmen|||0000-0003-2429-8297
  • Fernández-Alanin, Sonia
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Pérez, Antonio|||0000-0001-5528-1143
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
The effect of bariatric surgery on lipid profile and the qualitative characteristics of lipoproteins was analyzed in morbidly obese subjects. Thirteen obese patients underwent bariatric surgery. Plasma samples were obtained before surgery and at 6 and 12 months after the intervention. Thirteen healthy subjects comprised the control group. Lipid profile, hsCRP, and the composition and functional characteristics of VLDL, LDL, and HDL were assessed. At baseline, plasma from subjects with obesity had more triglycerides, VLDLc, and hsCRP, and less HDLc than the control group. These levels progressively normalized after surgery, although triglyceride and hsCRP levels remained higher than those in the controls. The main differences in lipoprotein composition between the obese subjects and the controls were increased apoE in VLDL, and decreased cholesterol and apoJ and increased apoC-III content in HDL. The pro-/anti-atherogenic properties of LDL and HDL were altered in the subjects with obesity at baseline compared with the controls, presenting smaller LDL particles that are more susceptible to modification and smaller HDL particles with decreased antioxidant capacity. Bariatric surgery normalized the composition of lipoproteins and improved the qualitative characteristics of LDL and HDL. In summary, patients with obesity present multiple alterations in the qualitative properties of lipoproteins compared with healthy subjects. Bariatric surgery reverted most of these alterations.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Cardiovascular Disease in Type 1 Diabetes Mellitus, Epidemiology and Management of Cardiovascular Risk

  • Colom, Cristina|||0000-0002-2926-4697
  • Rull, Anna|||0000-0002-8907-7754
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Divergent Effects of Glycemic Control and Bariatric Surgery on Circulating Concentrations of TMAO in Newly Diagnosed T2D Patients and Morbidly Obese

  • Canyelles, Marina|||0000-0002-0278-5337
  • Pérez, Antonio|||0000-0001-5528-1143
  • Junza, Alexandra
  • Miñambres, Inka|||0000-0002-0899-3938
  • Yanes, Oscar|||0000-0003-3695-7157
  • Sardà, Helena|||0000-0002-0138-8217
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
High circulating concentrations of the gut microbiota-derived metabolite trimethylamine N-oxide (TMAO) are significantly associated with the risk of obesity and type 2 diabetes (T2D). We aimed at evaluating the impact of glycemic control and bariatric surgery on circulating concentrations of TMAO and its microbiota-dependent intermediate, γ-butyrobetaine (γBB), in newly diagnosed T2D patients and morbidly obese subjects following a within-subject design. Based on HbA1c concentrations, T2D patients achieved glycemic control. However, the plasma TMAO and γBB concentrations were significantly increased, without changes in estimated glomerular filtration rate. Bariatric surgery was very effective in reducing weight in obese subjects. Nevertheless, the surgery reduced plasma γBB concentrations without affecting TMAO concentrations and the estimated glomerular filtration rate. Considering these results, an additional experiment was carried out in male C57BL/6J mice fed a Western-type diet for twelve weeks. Neither diet-induced obesity nor insulin resistance were associated with circulating TMAO and γBB concentrations in these genetically defined mice strains. Our findings do not support that glycemic control or bariatric surgery improve the circulating concentrations of TMAO in newly diagnosed T2D and morbidly obese patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Presence of Ceramidase Activity in Electronegative LDL

  • Puig Calvó, Núria|||0000-0001-8235-4934
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Estruch, Montserrat|||0000-0002-7162-4158
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Colomé, Núria
  • Canals, Francesc|||0000-0002-0650-1135
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL(-)) is a minor modified fraction of human plasma LDL with several atherogenic properties. Among them is increased bioactive lipid mediator content, such as lysophosphatidylcholine (LPC), non-esterified fatty acids (NEFA), ceramide (Cer), and sphingosine (Sph), which are related to the presence of some phospholipolytic activities, including platelet-activating factor acetylhydrolase (PAF-AH), phospholipase C (PLC), and sphingomyelinase (SMase), in LDL(-). However, these enzymes' activities do not explain the increased Sph content, which typically derives from Cer degradation. In the present study, we analyzed the putative presence of ceramidase (CDase) activity, which could explain the increased Sph content. Thin layer chromatography (TLC) and lipidomic analysis showed that Cer, Sph, and NEFA spontaneously increased in LDL(-) incubated alone at 37 °C, in contrast with native LDL(+). An inhibitor of neutral CDase prevented the formation of Sph and, in turn, increased Cer content in LDL(-). In addition, LDL(-) efficiently degraded fluorescently labeled Cer (NBD-Cer) to form Sph and NEFA. These observations defend the existence of the CDase-like activity's association with LDL(-). However, neither the proteomic analysis nor the Western blot detected the presence of an enzyme with known CDase activity. Further studies are thus warranted to define the origin of the CDase-like activity detected in LDL(-).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Can Electronegative LDL Act as a Multienzymatic Complex?

  • Benitez, Sonia|||0000-0003-3565-0743
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Solé, Arnau|||0009-0007-6517-6188
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
Electronegative LDL (LDL(-)) is a minor form of LDL present in blood for which proportions are increased in pathologies with increased cardiovascular risk. In vitro studies have shown that LDL(-) presents pro-atherogenic properties, including a high susceptibility to aggregation, the ability to induce inflammation and apoptosis, and increased binding to arterial proteoglycans; however, it also shows some anti-atherogenic properties, which suggest a role in controlling the atherosclerotic process. One of the distinctive features of LDL(-) is that it has enzymatic activities with the ability to degrade different lipids. For example, LDL(-) transports platelet-activating factor acetylhydrolase (PAF-AH), which degrades oxidized phospholipids. In addition, two other enzymatic activities are exhibited by LDL(-). The first is type C phospholipase activity, which degrades both lysophosphatidylcholine (LysoPLC-like activity) and sphingomyelin (SMase-like activity). The second is ceramidase activity (CDase-like). Based on the complementarity of the products and substrates of these different activities, this review speculates on the possibility that LDL(-) may act as a sort of multienzymatic complex in which these enzymatic activities exert a concerted action. We hypothesize that LysoPLC/SMase and CDase activities could be generated by conformational changes in apoB-100 and that both activities occur in proximity to PAF-AH, making it feasible to discern a coordinated action among them.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PCSK9 plasma concentration is associated with epicardial adipose tissue volume and metabolic control in patients with type 1 diabetes

  • Sardà, Helena|||0000-0002-0138-8217
  • Colom, Cristina|||0000-0002-2926-4697
  • Benitez, Sonia|||0000-0003-3565-0743
  • Carreras, Gemma|||0000-0002-6718-8381
  • Amigó, Judit|||0000-0003-2407-1906
  • Miñambres, Inka|||0000-0002-0899-3938
  • Viladés Medel, David|||0000-0002-3638-9703
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Patients with type 1 diabetes (T1D) have a greater risk of cardiovascular disease. Proconvertase subtilisin-kexin 9 (PCSK9) is involved in the atherosclerosis process. This study aimed to determine the relationship between PCSK9 levels and epicardial adipose tissue (EAT) volume and cardiometabolic variables in patients with T1D. This was an observational cross-sectional study including 73 patients with T1D. Clinical, biochemical and imaging data were collected. We divided the patients into two groups according to their glycemic control and the EAT index (iEAT) percentile. We performed a correlation analysis between the collected variables and PCSK9 levels; subsequently, we performed a multiple regression analysis with the significant parameters. The mean age was 47.6 ± 8.5 years, 58.9% were men, and the BMI was 26.9 ± 4.6 kg/m 2. A total of 31.5%, 49.3% and 34.2% of patients had hypertension, dyslipidemia and smoking habit, respectively. The PCSK9 concentration was 0.37 ± 0.12 mg/L, which was greater in patients with worse glycemic control (HbA1c.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased sLRP1 and decreased atrial natriuretic peptide plasma levels in newly diagnosed T2DM patients are normalized after optimization of glycemic control

  • García, Eduardo
  • Gil, Pedro|||0000-0003-3707-7450
  • Miñambres, Inka|||0000-0002-0899-3938
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Rodríguez, Claudia
  • Claudi, Lene
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Benitez, Sonia|||0000-0003-3565-0743
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Garcia-Moll, Xavier|||0000-0001-7837-8378
  • Viladés Medel, David|||0000-0002-3638-9703
  • Pérez, Antonio|||0000-0001-5528-1143
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Low-density lipoprotein receptor-related protein 1 (LRP1) negatively modulates circulating atrial natriuretic peptide (ANP) levels. Both molecules are involved in the regulation of cardiometabolism. To evaluate soluble LRP1 (sLRP1) and ANP levels in people with newly diagnosed type 2 diabetes mellitus (T2DM) and determine the effects of metabolic optimization. This single-center longitudinal observational study recruited patients with newly diagnosed T2DM (n = 29, HbA1c.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LDL binding to cell receptors and extracellular matrix is proatherogenic in obesity but improves after bariatric surgery

  • Jayaraman, Shobini|||0000-0003-1616-5347
  • Pérez, Antonio|||0000-0001-5528-1143
  • Miñambres, Inka|||0000-0002-0899-3938
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gursky, Olga
Obesity is a major global public health issue involving dyslipidemia, oxidative stress, inflammation, and increased risk of CVD. Weight loss reduces this risk, but the biochemical underpinnings are unclear. We explored how obesity and weight loss after bariatric surgery influence LDL interactions that trigger proatherogenic versus anti-atherogenic processes. LDL was isolated from plasma of six patients with severe obesity before (basal) and 6-12 months after bariatric surgery (basal BMI ¼ 42.7 kg/m; 6-months and 12-months postoperative BMI ¼ 34.1 and 30 kg/m). Control LDL were from six healthy subjects (BMI ¼ 22.6 kg/m). LDL binding was quantified by ELISA; LDL size and charge were assessed by chromatography; LDL biochemical composition was determined. Compared to controls, basal LDL showed decreased nonatherogenic binding to LDL receptor, which improved postoperatively. Conversely, basal LDL showed increased binding to scavenger receptors LOX1 and CD36 and to glycosaminoglycans, fibronectin and collagen, which is proatherogenic. One year postoperatively, this binding decreased but remained elevated, consistent with elevated lipid peroxidation. Serum amyloid A and nonesterified fatty acids were elevated in basal and postoperative LDL, indicating obesity-associated inflammation. Aggregated and electronegative LDL remained elevated, suggesting proatherogenic processes. These results suggest that obesity-induced inflammation contributes to harmful LDL alterations that probably increase the risk of CVD. We conclude that in obesity, LDL interactions with cell receptors and extracellular matrix shift in a proatherogenic manner but are partially reversed upon postoperative weight loss. These results help explain why the risk of CVD increases in obesity but decreases upon weight loss.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating lipoprotein-carried miRNome analysis reveals novel VLDL-enriched microRNAs that strongly correlate with the HDL-microRNA profile

  • Rossi-Herring, Guido|||0000-0003-1454-0916
  • Belmonte, Thalia|||0000-0003-1241-6073
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Benitez, Sonia|||0000-0003-3565-0743
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Crespo García, Javier|||0000-0001-8248-0172
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the bibliography on this topic is scarce and shows a high variability between independent investigations. In addition, the miRNA profiles of the LDL and VLDL fractions have not been completely elucidated. Here, we profiled the human circulating lipoprotein-carried miRNome. Lipoprotein fractions (VLDL, LDL and HDL) were isolated from the serum of healthy subjects by ultracentrifugation and purified by size-exclusion chromatography. A panel of 179 miRNAs commonly expressed in circulation was evaluated in the lipoprotein fractions using quantitative real-time PCR (qPCR) assays. A total of 14, 4 and 24 miRNAs were stably detected in the VLDL, LDL and HDL fractions, respectively. VLDL- and HDL-miRNA signatures were highly correlated (rho 0.814), and miR-16-5p, miR-142-3p, miR-223-3p and miR-451a were among the top 5 expressed miRNAs in both fractions. miR-125a-5p, miR-335-3p and miR-1260a, were detected in all lipoprotein fractions. miR-107 and miR-221-3p were uniquely detected in the VLDL fraction. HDL showed the larger number of specifically detected miRNAs (n = 13). Enrichment in specific miRNA families and genomic clusters was observed for HDL-miRNAs. Two sequence motifs were also detected for this group of miRNAs. Functional enrichment analysis including the miRNA signatures from each lipoprotein fraction suggested a potential role in mechanistic pathways previously associated with cardiovascular disease: fibrosis, senescence, inflammation, immune response, angiogenesis, and cardiomyopathy. Collectively, our results not only support the role of lipoproteins as circulating miRNA carriers but also describe for the first time the role of VLDL as a miRNA transporter.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.